RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Neuphoria Therapeutics Stock

Neuphoria Therapeutics ROE 2025

Neuphoria Therapeutics ROE

-0.96

Ticker

NEUP

ISIN

US64136E1029

In 2025, Neuphoria Therapeutics's return on equity (ROE) was -0.96, a 151.29% increase from the -0.38 ROE in the previous year.

Neuphoria Therapeutics Aktienanalyse

What does Neuphoria Therapeutics do?

Neuphoria Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Neuphoria Therapeutics's Return on Equity (ROE)

Neuphoria Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Neuphoria Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Neuphoria Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Neuphoria Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Neuphoria Therapeutics stock

What is the ROE (Return on Equity) of Neuphoria Therapeutics this year?

The ROE of Neuphoria Therapeutics this year is -0.96 undefined.

How has the Return on Equity (ROE) of Neuphoria Therapeutics developed compared to the previous year?

The ROE of Neuphoria Therapeutics has increased by 151.29% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Neuphoria Therapeutics?

A high ROE indicates that Neuphoria Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Neuphoria Therapeutics?

A low ROE can indicate that Neuphoria Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Neuphoria Therapeutics affect the company?

A change in ROE (Return on Equity) of Neuphoria Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Neuphoria Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Neuphoria Therapeutics?

Some factors that can influence Neuphoria Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Neuphoria Therapeutics pay?

Over the past 12 months, Neuphoria Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neuphoria Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Neuphoria Therapeutics?

The current dividend yield of Neuphoria Therapeutics is .

When does Neuphoria Therapeutics pay dividends?

Neuphoria Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Neuphoria Therapeutics?

Neuphoria Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Neuphoria Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Neuphoria Therapeutics located?

Neuphoria Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Neuphoria Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Neuphoria Therapeutics from 6/21/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/21/2025.

When did Neuphoria Therapeutics pay the last dividend?

The last dividend was paid out on 6/21/2025.

What was the dividend of Neuphoria Therapeutics in the year 2024?

In the year 2024, Neuphoria Therapeutics distributed 0 USD as dividends.

In which currency does Neuphoria Therapeutics pay out the dividend?

The dividends of Neuphoria Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Neuphoria Therapeutics

Our stock analysis for Neuphoria Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuphoria Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.